Press Room

Bioprocessing Summit Europe

Start
Tuesday, March 20, 2018 - 00:00
End
Thursday, March 22, 2018 - 00:00
Location: Lisbon, Portugal
Booth Number: 9

Bioprocessing Summit Europe brings together leading bioprocessing scientists to share day-to-day challenges and practical solutions for today's bioprocessing needs. 

Hovione is present at the Bioprocessing Summit Europe with a Booth (# 9) and with a presentation by Márcio Temtem.

 

HOVIONE PRESENTATION

Spray drying - a viable alternative to biopharmaceuticals?

Date/Time: Thursday, March 22nd, 9:30
Room: White Plains 5

Presentation abstract:

Spray drying is presently one of the most exciting technologies in the pharmaceutical industry with several commercial products approved each year.

The relevance of the technology is in part explained by the fact it is a scalable drying process suitable to convert liquid streams into dry powders with a broad range of properties. Such flexibility led to its application in a variety of pharmaceutical formulations: from very fine powders for inhalation to large particles for direct compression, or from solid dispersions for enhanced bioavailability to microcapsules for controlled release. The process considers the fine spraying of a liquid into a hot gas, evaporating, drying and collecting the solid particles from the gas stream. The process is very fast and product-gas contact very short. Due to the intensive evaporative during the drying, temperature in the droplet remains relatively low, making the process suitable for the processing of thermos labile materials like biopharmaceuticals (e.g. proteins, peptides or antibodies).  In this talk the authors will present examples of such processes and the advantages of spray drying over conventional technologies.

 

If you would like to discuss with us your projects and to find how Hovione can help, schedule a meeting with us.

 

Our colleague, Marcel Hogerheide will be pleased to meet you.

Marcel Hogerheide  | Hovione

Marcel Hogerheide

Head of Account Management & Business Development
 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025